Two Sigma Advisers LP Has $17.85 Million Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Two Sigma Advisers LP lessened its stake in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 20.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 604,900 shares of the company's stock after selling 152,800 shares during the period. Two Sigma Advisers LP owned 1.21% of Immunocore worth $17,845,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMCR. Groupama Asset Managment acquired a new stake in shares of Immunocore in the fourth quarter valued at $17,700,000. Deep Track Capital LP acquired a new position in Immunocore during the fourth quarter worth about $15,322,000. Tang Capital Management LLC grew its holdings in Immunocore by 40.7% during the fourth quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock worth $45,890,000 after acquiring an additional 450,000 shares during the period. Point72 Asset Management L.P. acquired a new position in Immunocore during the fourth quarter worth about $11,897,000. Finally, T. Rowe Price Investment Management Inc. boosted its position in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after purchasing an additional 200,373 shares in the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Trading Up 5.2%

Shares of NASDAQ IMCR traded up $1.61 during mid-day trading on Tuesday, hitting $32.77. 162,798 shares of the company traded hands, compared to its average volume of 387,796. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $49.05. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -34.49 and a beta of 0.75. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The business has a 50 day moving average of $29.06 and a two-hundred day moving average of $29.95.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. Immunocore's quarterly revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.49) earnings per share. On average, sell-side analysts anticipate that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were purchased at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the transaction, the director now owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.40% of the stock is owned by insiders.

Analyst Ratings Changes

IMCR has been the subject of several recent research reports. Oppenheimer increased their target price on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. dropped their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a report on Monday, April 14th. Mizuho cut their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Deutsche Bank Aktiengesellschaft began coverage on Immunocore in a research note on Tuesday. They set a "buy" rating and a $65.00 price objective for the company. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.